condition Interstitial Lung Disease

Overview

Interstitial lung disease (ILD) is the name for a group of diseases characterized by inflammation and scarring of the lungs. The scarring and stiffness develop after a long period of exposure to things like mold, radiation, certain chemicals or vapors, and some medications. Some people may inherit ILD from their family or develop it as a result of an autoimmune disease like lupus. Sometimes the cause is unknown, like in idiopathic pulmonary fibrosis (IPF). Most people with ILD have shortness of breath. Other symptoms can be a dry cough, tiredness, chest discomfort, and a “clubbing” of the fingers or toes. If not treated, ILD can cause high blood pressure, heart failure, and even death. A doctor can listen for “crackles” in the lungs and can order a CT scan to look for lung scarring. Other tests can measure blood oxygen levels, lung function, and exercise tolerance. No medication can cure ILD, but treatments to decrease inflammation, control symptoms, and prevent or reduce future lung scarring are available.

Drug Therapies

  • Bosentan

    bosentan

    Ambrisentan is an endothelin receptor antagonist approved to treat adults and children 3 years and older with WHO group 1 pulmonary arterial hypertension. By increasing pulmonary vasodilation, it can improve exercise tolerance and quality of life.
    Manufacturer:
    Misc
    Route of Administration: 
    Oral
    Site of Care:
    Outpatient
    Website: 
    • https://www.tracleer.com/
    phone: 
    1-866-359-2612
    Enrollment Forms:
    Synergen Prescription Form
    Patient Support Form

    Approved Indication:

    • treatment of pulmonary arterial hypertension (WHO group 1) in adults to improve exercise ability and to decrease clinical worsening
    • treatment of pulmonary arterial hypertension (WHO group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance which is expected to result in an improvement in exercise ability

    Conditions:

    • Pulmonary Arterial Hypertension
      less details
    • CellCept

      CellCept (mycophenolate mofetil)

      CellCept (mycophenolate mofetil) is a prodrug of mycophenolic acid, an antiproliferative agent approved to prevent rejection of a transplanted organ. Because of its mechanism, CellCept is also widely used in the management of certain autoimmune disorders.
      Manufacturer:
      Genentech
      Route of Administration: 
      Oral
      Site of Care:
      Outpatient
      Website: 
      • https://www.cellcept.com/
      Enrollment Forms:
      Synergen Prescription Form
      Patient Support Form

      Approved Indication:

      prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogenic kidney, heart, or liver transplants, in combination with other immunosuppressants

      Conditions:

      • Solid Organ Transplant

        Therapeutic Area:

        • Gastroenterology
        • Rheumatology
        • Dermatology
        • Hepatology
        • Nephrology
        less details
      • Esbriet

        Esbriet (pirfenidone)

        Esbriet (pirfenidone) is an antifibrotic medication that treats idiopathic pulmonary fibrosis by reducing the build-up of scar tissue in the lungs.
        Manufacturer:
        Genentech
        Route of Administration: 
        Oral
        Site of Care:
        Outpatient
        Website: 
        • https://www.esbriet.com/
        phone: 
        888-941-3331
        Enrollment Forms:
        Synergen Prescription Form
        Patient Support Form

        Approved Indication:

        treatment of idiopathic pulmonary fibrosis

        Conditions:

        • Idiopathic Pulmonary Fibrosis (IPF)
          less details
        • Gengraf

          Gengraf (cyclosporine, modified)

          Gengraf (cyclosporine, modified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
          Manufacturer:
          Misc.
          Route of Administration: 
          Oral
          Site of Care:
          Outpatient
          Website: 
            Enrollment Forms:
            Synergen Prescription Form

            Approved Indication:

            • prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants
            • treatment of patients with severe, active rheumatoid arthritis where the disease has not adequately responded to methotrexate
            • treatment of adult, nonimmunocompromised patients with severe, recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy or for whom other systemic therapies are contraindicated or cannot be tolerated

            Conditions:

            • Solid Organ Transplant
            • Rheumatoid Arthritis
            • Plaque Psoriasis

              Therapeutic Area:

              • Cardiology
              • Dermatology
              • Hepatology
              • Nephrology
              • Rheumatology
              • Transplant
              less details
            • Jascayd

              Jascayd (nerandomilast)

              Jascayd (nerandomilast) is an inhibitor of the enzyme phosphodiesterase 4 (PDE4), an important contributor to inflammation and fibrosis. By blocking the action of PDE4, Jascayd can slow the development of new pulmonary fibrosis.
              Manufacturer:
              Boehringer Ingelheim
              Route of Administration: 
              Oral
              Site of Care:
              Outpatient
              Website: 
              • https://patient.booehringer-ingelheim.com/us/products/jascayd/
              phone: 
              1-844-JASCAYD (1-844-527-2293)
              Enrollment Forms:
              Synergen Prescription Form
              Patient Support Form

              Approved Indication:

              treatment of adult patients with idiopathic pulmonary fibrosis

              Conditions:

              • Idiopathic Pulmonary Fibrosis
                less details
              • Neoral

                Neoral (cyclosporine, modified)

                Neoral (cyclosporine, modified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
                Manufacturer:
                misc.
                Route of Administration: 
                Oral
                Site of Care:
                Outpatient
                Website: 
                  Enrollment Forms:
                  Synergen Prescription Form

                  Approved Indication:

                  • prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants
                  • treatment of patients with severe, active rheumatoid arthritis where the disease has not adequately responded to methotrexate
                  • treatment of adult, nonimmunocompromised patients with severe, recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy or for whom other systemic therapies are contraindicated or cannot be tolerated

                  Conditions:

                  • Solid Organ Transplant
                  • Rheumatoid Arthritis
                  • Plaque Psoriasis

                    Therapeutic Area:

                    • Cardiology
                    • Dermatology
                    • Hepatology
                    • Nephrology
                    • Rheumatology
                    • Transplant
                    less details
                  • Ofev

                    Ofev (nintedanib)

                    Ofev (nintedanib) is an antifibrotic medication that treats interstitial lung disease and idiopathic pulmonary fibrosis by reducing the build-up of scar tissue in the lungs.
                    Manufacturer:
                    Boehringer Ingelheim
                    Route of Administration: 
                    Oral
                    Site of Care:
                    Outpatient
                    Website: 
                    • https://pro.boehringer-ingelheim.com/us/products/ofev/
                    phone: 
                    855-297-5906 (BI Cares)
                    Enrollment Forms:
                    Synergen Prescription Form
                    Patient Support Form

                    Approved Indication:

                    • treatment of idiopathic pulmonary fibrosis in adults
                    • treatment of chronic fibrosis interstitial lung diseases with a progressive phenotype in adults
                    • slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease in adults

                    Conditions:

                    • Idiopathic Pulmonary Fibrosis (IPF)
                    • Interstitial Lung Disease (ILD)
                      less details
                    • Sandimmune

                      Sandimmune (cyclosporine, unmodified)

                      Sandimmune (cyclosporine, UNmodified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
                      Manufacturer:
                      Misc.
                      Route of Administration: 
                      Oral, Intravenous
                      Site of Care:
                      Outpatient, Inpatient
                      Website: 
                        Enrollment Forms:
                        Synergen Prescription Form

                        Approved Indication:

                        prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants in combination with adrenal corticosteroids

                        Conditions:

                        • Solid Organ Transplant

                          Therapeutic Area:

                          • Cardiology
                          • Hepatology
                          • Nephrology
                          • Transplant
                          less details

                        Resources

                        Understanding a diagnosis can feel overwhelming. These resources link to well-established organizations, for in-depth education, research, and support.

                        American Lung Association
                        Pulmonary Fibrosis Foundation

                        Stay Connected

                        Get the latest news and updates

                        Contact Us Now